Press Release (August 21st): Launch of the website ose-immuno-ensemble to inform all stakeholders of OSE Immunotherapeutics ahead of the September 30, 2025 General Meeting

[Download the press release]

Dominique Costantini, Emile Loria, and Alexis Peyroles, founding members and executives of OSE Immunotherapeutics (OSE) from 2012 to 2024, announce the launch of the website ose-immuno-ensemble.com, ahead of the General Meeting on September 30, 2025, which will be decisive for the company’s strategy.
 
Together holding 20% of the capital and 24% of the voting rights, they signed a shareholders’ agreement forming a action in concert on May 27, 2025. On the website ose-immuno-ensemble.com, they present:

• Their disagreement with OSE’s Board of Directors regarding strategy, particularly concerning the clinical development of Lusvertikimab, a first-in-class treatment for ulcerative colitis;
• Their unsuccessful attempts to engage in dialogue with the Board of Directors in April and May;
• Their conclusion, at the end of May, that the only option to change OSE’s strategy is to change the Board of Directors;
• Biographies of the five directors whose appointments they sought in June and intend to propose at the General Meeting on September 30, 2025.

They will regularly update the website until September 30, including, at the end of August, with their proposed resolutions for the General Meeting.

OSE is a biotechnology company specializing in immuno-oncology and immuno-inflammation.

Located in Nantes and in Paris, the company is listed on Euronext. From 2012 to January 2025, Dominique Costantini, Emile Loria, and Alexis Peyroles held the following roles:

• Emile Loria: Non-Executive Chairman of the Board from April 2012 to April 2018
• Dominique Costantini:
  • Board Member from April 2012 to June 2024
  • Chair of the Board from April 2018 to June 2024
  • Chief Executive Officer (CEO) from April 2012 to April 2018
  • Director of Strategy and Development from April 2012 to October 2024
  • Consultant until January 2025 (publication of Phase 2 results for Lusvertikimab)
• Alexis Peyroles:
  • Chief Financial and Operating Officer from September 2013 to May 2016
  • Deputy CEO in charge of Finance, Business Development, and Operations from May
  • 2016 to April 2018
  • Chief Executive Officer (CEO) from April 2018 to January 2022
  • Board Member from May 2016 to January 2022

 
Press contact: Séverine Besse-Le Saux – severine@mrsbesse.com, +33 6 22 59 13 71